Why Cetero Research is the Choice for Generic Companies
We’ll take you beyond bioequivalence and right through your regulatory submission. At Cetero, we specialize in early phase, and that means we’re better prepared than any other CRO to move you quickly through proof of bioequivalence and put you on the fast track to regulatory submission with our First to File service.
In fact, we can consistently provide final study reports 25 days or less from the initial dosing of clinical study participants – an unprecedented achievement in the industry, compared to typical timelines of 56-63 days. No other CRO has the resources or capabilities to match this unique service on a routine basis.
First to File leads straight to first marketing approval, and that gives you a 180-day period of marketing exclusivity in which no competing generic product can be sold. That gives you a tremendous head start gaining physician and payer acceptance, as well as an opportunity to generate substantial profits before other generic products enter the market.
A 25-day completion is by no means easy to achieve, and that makes it critical to choose Cetero to put the pieces together in the right order, at the right times. Our detailed, coordinated project and communication plans involve multiple operational functions and multiple Cetero sites. Since the successful completion of your First to File initiative requires extraordinary coordination and dedicated resources, many of the activities are planned to the hour of duration rather than the typical duration unit of days.
So don’t lose a minute. Contact Cetero today and learn how we can make your next product First to File.
